There isn't much work left to do with Covid for Humanigen from a science aspect. They've completed a phase III trial and the government is continuing with the ACTIV-5. Now they just have to wait for approval.
Humanigen's CAR-T and oncology work is still in its infancy. Lenz's phase II CAR-T trial is a huge undertaking. It is exciting but not nearly as fast-paced as Covid.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.